Signature-based approaches for informed drug repurposing: targeting CNS disorders

Area of Science:

• Neuroscience
• Pharmacology
• Bioinformatics

Background:

• Central nervous system (CNS) disorders, particularly psychiatric illnesses, have limited disease-altering treatments.
• The slow, expensive drug development process and poor mechanistic understanding hinder therapeutic progress.
• Drug repurposing presents a cost-effective and time-efficient alternative to de novo drug development.

Purpose of the Study:

• To review signature-based in silico approaches for drug repurposing in CNS disorders.
• To discuss the integration of omics data with these computational strategies.
• To highlight the potential for evidence-based drug repurposing for psychiatric disorders.

Main Methods:

• Utilizing structural and transcriptomic signatures for drug characterization.
• Employing ontological integration with big data ('omics') platforms.
• In silico analysis of drug repurposing strategies.

Main Results:

• Signature-based approaches combined with omics data offer a powerful tool for drug discovery.
• These methods facilitate the identification of drugs with potential therapeutic applications.
• Integration of omics and computational tools addresses knowledge gaps in CNS drug development.

Conclusions:

• In silico drug repurposing, leveraging omics data, provides a promising translational strategy.
• This approach can accelerate the identification of novel therapies for psychiatric disorders.
• Merging omics platforms with patient-specific disease signatures facilitates evidence-based treatment discovery.